Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2007-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-006-0306-6PMID 16937105
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.

  2006cited by this paper
• Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors

  2005cited by this paper
• Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

  2005cited by this paper
• Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?

  2005cited by this paper
• Treatment of metastatic neuroendocrine carcinomas based on WHO classification.

  2005cited by this paper
• Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor

  2005cited by this paper
• Pathology and genetics of tumours of the lung , pleura, thymus and heart

  2004cited by this paper
• Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin

  2003cited by this paper
• Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours.

  2002cited by this paper
• Chemotherapy and biotherapy in the treatment of neuroendocrine tumours

  2001cited by this paper
• Treatment with cisplatin and etoposide in patients with neuroendocrine tumors

  2001cited by this paper
• Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.

  2001cited by this paper
• Chemotherapy in the Treatment of Neuroendocrine Malignant Tumors

  2000cited by this paper
• Histological Classification of Endocrine Tumours

  2000cited by this paper
• Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

  1999cited by this paper
• Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma.

  1998cited by this paper
• A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group.

  1995cited by this paper
• Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon‐alpha‐2a: A study by the Italian trials in Medical Oncology Group

  1993cited by this paper
• Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.

  1992cited by this paper
• Chemotherapy with 5-fluorouracil and streptozotocin in carcinoid tumors of gastrointestinal origin: experiences with 13 patients.

  1991cited by this paper
• Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

  1991cited by this paper
• International Histological Classification of Tumours

  1981cited by this paper
• WHO Handbook for Reporting Results of Cancer Treatment

  1980cited by this paper

• Medical Management of Well-Differentiated Pancreatic Neuroendocrine Tumors: From Conventional Therapies to Emerging Strategies

  2026cites this paper
• Advances in Non-Surgical Management of Neuroendocrine Neoplasms

  2025cites this paper
• Predictive factors for efficacy of oxaliplatin-based chemotherapy in advanced well-differentiated neuroendocrine tumors: an observational cohort study and meta-analysis

  2025cites this paper
• When rarity meets thoracic cancers: a narrative review from ITMIG 2024

  2025cites this paper
• Treatment of Pancreatic Neuroendocrine Tumors: Beyond Traditional Surgery and Targeted Therapy

  2025cites this paper
• Pulmonary Carcinoids: Diagnostic and Therapeutic Approach

  2025cites this paper
• High-grade gastro-entero-pancreatic neuroendocrine neoplasms: an overlooked population in interventional clinical trials. A systematic review.

  2025cites this paper
• Capecitabine and temozolomide or temozolomide alone in patients with atypical carcinoids

  2025cites this paper
• Bone metastases from endocrine cancer: advances in diagnosis, treatment, and prevention

  2025cites this paper
• Imaging of Neuroendocrine Neoplasms; Principles of Treatment Strategies. What Referring Clinicians Want to Know

  2024cites this paper
• Lung NETs and GEPNETs: One Cancer with Different Origins or Two Distinct Cancers?

  2024cites this paper
• An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and Prospects

  2024cites this paper
• Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives

  2024cites this paper
• Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET)

  2024cites this paper
• Current and emerging strategies for the management of advanced/metastatic lung neuroendocrine tumors.

  2024cites this paper
• Neuroendokrine Tumoren der Lunge: State of the Art

  2024cites this paper
• Advancements in Neuroendocrine Neoplasms: Imaging and Future Frontiers

  2024cites this paper
• Review of the Literature and Current State of Knowledge on the Management of Lung Neuroendocrine Neoplasms

  2023cites this paper
• Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms

  2023cites this paper
• Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma

  2023cites this paper
• Integrating Functional Imaging and Molecular Profiling for Optimal Treatment Selection in Neuroendocrine Neoplasms (NEN)

  2023cites this paper
• Therapy Sequencing in Patients With Advanced Neuroendocrine Neoplasms.

  2023cites this paper
• Digestive MiNENs: Could histological classification and molecular characterization drive clinical outcome and therapeutic approach?

  2023cites this paper
• Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review

  2023influential citation
• Peptide Receptor Radionuclide Therapy Using 177 Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment

  2022cites this paper
• Rare Bone Metastasis of Neuroendocrine Tumors of Unknown Origin: A Case Report and Literature Review

  2022cites this paper
• Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.

  2022cites this paper
• Long‐term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu‐octreotate peptide radionuclide therapy

  2022cites this paper
• Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives

  2022cites this paper
• Metronomic chemotherapy in patients with advanced neuroendocrine tumors: A single‐center retrospective analysis

  2022cites this paper
• Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors

  2022cites this paper
• NETs of the Lung

  2021cites this paper
• State of the art and future directions in the systemic treatment of neuroendocrine neoplasms

  2021influential citation
• Chemotherapy in NEN: still has a role?

  2021influential citation
• Metastatic well-differentiated pancreatic neuroendocrine tumors to the liver: a narrative review of systemic and surgical management

  2021cites this paper
• Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions

  2021cites this paper
• How I Treat Neuroendocrine Tumors

  2021cites this paper
• Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma

  2021cites this paper
• Neuroendocrine Neoplasms (NENs)

  2021cites this paper
• New Concepts in Pathology

  2021cites this paper
• Efficacy of FOLFOX Chemotherapy in Metastatic Enteropancreatic Neuroendocrine Tumors

  2021cites this paper
• An Overview of Pancreatic Neuroendocrine Tumors

  2021cites this paper
• Therapy in Poorly Differentiated Neuroendocrine Neoplasms (NEN G3)

  2021cites this paper
• Neuroendocrine Carcinomas of the Digestive Tract: What Is New?

  2021cites this paper
• [The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020)].

  2021cites this paper
• Oxaliplatin and 5-Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A Multicenter National Retrospective Study from the French Group of Endocrine Tumors

  2021cites this paper
• Gastro-entero-pancreatic Neuroendocrine Tumors

  2021cites this paper
• Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study.

  2021cites this paper
• Medical Treatment of Advanced Pancreatic Neuroendocrine Neoplasms

  2020cites this paper
• Efficacy and Toxicity of 5-Fluorouracil–Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms

  2020cites this paper
• Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).

  2020cites this paper
• Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review

  2020cites this paper
• Phase II study of temozolomide monotherapy in patients with extrapulmonary poorly differentiated neuroendocrine carcinoma that were resistant to platinum-based chemotherapy

  2020cites this paper
• Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Advanced Neuroendocrine Tumours (NETs) in a Limited Resource Environment

  2020cites this paper
• Recent Advances in the Management of Typical and Atypical Lung Carcinoids.

  2020cites this paper
• Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments

  2020cites this paper
• Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis

  2020cites this paper
• Oncological management of advanced neuroendocrine tumours (Review).

  2020cites this paper
• New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms

  2020cites this paper
• The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors

  2020cites this paper
• Kinome rewiring during acquired drug resistance in neuroendocrine neoplasms.

  2020cites this paper
• Systemic treatment of pancreatic neuroendocrine tumors

  2019cites this paper
• Cysteine metabolism and pancreatic neuroendocrine tumors (PNETs) chemoresistance

  2019cites this paper
• The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors

  2019cites this paper
• Treatment strategies for neuroendocrine liver metastases: an update

  2019cites this paper
• O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET).

  2019cites this paper
• Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma.

  2019cites this paper
• Systemic treatment for lung carcinoids: from bench to bedside

  2019cites this paper
• Management of Pancreatic and Duodenal Neuroendocrine Tumors

  2018cites this paper
• Management of Ileal, Appendiceal and Colorectal Neuroendocrine Tumors

  2018cites this paper
• Therapy for Metastatic Disease: Bronchi

  2018cites this paper
• 55 – Neuroendocrine Tumors of the Lung Other Than Small Cell Lung Cancer

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• Ex vivo activity of cytotoxic drugs and targeted agents in small intestinal neuroendocrine tumors.

  2018cites this paper
• Novel fluoropyrimidine-based chemotherapy for advanced well-differentiated neuroendocrine tumors: a clinical update

  2018cites this paper
• Metastatic neuroendocrine pancreatic tumor – Case report

  2018cites this paper
• Is There A Place for Systemic Chemotherapy and Targeted Agents in Metastatic Small Intestine Neuroendocrine Tumors?

  2018cites this paper
• An update on the management of pancreatic neuroendocrine tumors

  2018cites this paper
• Open issues on G3 neuroendocrine neoplasms: back to the future.

  2018cites this paper
• Well‐differentiated bronchial neuroendocrine tumors: Clinical management and outcomes in 105 patients

  2018cites this paper
• Current Chemotherapy Use in Neuroendocrine Tumors.

  2018cites this paper
• A case report of successful treatment of metastatic gastral neuroendocrine carcinoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib

  2018influential citation
• Small Intestinal Neuroendocrine Tumors : Clinical Studies, Novel Serum Biomarkers and Sensitivity to Cytotoxic and Targeted Agents

  2017cites this paper
• Colorectal neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).

  2017cites this paper
• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy

  2017cites this paper
• Neuroendokrines Karzinom des Analkanals: eine seltene Differenzialdiagnose – Sicht des Gastroenterologen

  2017cites this paper
• Pancreatic neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).

  2017cites this paper
• Functional pancreatic neuroendocrine tumour causing Cushing’s syndrome: the effect of chemotherapy on clinical symptoms

  2017cites this paper
• The role of multimodal treatment in patients with advanced lung neuroendocrine tumors.

  2017cites this paper
• Treatment Patterns and Burden of Illness in Patients Initiating Targeted Therapy or Chemotherapy for Pancreatic Neuroendocrine Tumors

  2017cites this paper
• Progress in diagnosis and therapy of advanced pulmonary carcinoid

  2017cites this paper
• Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study

  2017cites this paper
• Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas

  2017cites this paper
• Metronomic and metronomic-like therapies in neuroendocrine tumors - Rationale and clinical perspectives.

  2017cites this paper
• Diagnostic and therapeutic guidelines for gastro-entero- -pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours)

  2017cites this paper
• A Step-by-Step Clinical Approach for the Management of Neuroendocrine Tumours

  2017cites this paper
• Chemotherapy in NETs: When and how

  2017cites this paper
• Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours).

  2017cites this paper
• Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic

  2017cites this paper
• Neuroendocrine tumors of the thymus: the oncologist point of view.

  2017cites this paper